BACKGROUND: Interleukin 10 (IL-10) is considered an immune modulator cytokine, showing both antitumor and pro-tumor characteristics. Its role in the pathogenesis and progression of colorectal cancer depends on microenvironmental milieu. MATERIALS AND METHODS: A case-control study with 58 newly diagnosed colorectal cancer (CRC) patients, and 30 healthy individuals was conducted to compare the serum IL-10 levels between patients and controls. Furthermore, the correlation of the cytokine levels with the pathological features and prognosis of the CRC was investigated. IL-10 levels in the sera of patients and controls were measured by Enzyme-linked immunosorbent assay. RESULTS: Mean serum IL-10 levels were significantly lower in CRC patients than in controls (P = 0.04). CRC patients with worse prognosis at the time of diagnosis tend to have higher levels of circulating IL-10 than those with better prognosis (P = 0.008). Receiver operating characteristics curve analysis demonstrated that IL-10 levels in the sera of CRC patients can be used as a prognostic biomarker in CRC patients (area under the curve = 0.71; P = 0.01). CONCLUSIONS: Our results demonstrated a dual association of serum IL-10 levels in the initiation and progression of CRC. While lower IL-10 levels were associated with higher risk of the disease, its higher levels were associated with a poorer prognosis.
BACKGROUND:Interleukin 10 (IL-10) is considered an immune modulator cytokine, showing both antitumor and pro-tumor characteristics. Its role in the pathogenesis and progression of colorectal cancer depends on microenvironmental milieu. MATERIALS AND METHODS: A case-control study with 58 newly diagnosed colorectal cancer (CRC) patients, and 30 healthy individuals was conducted to compare the serum IL-10 levels between patients and controls. Furthermore, the correlation of the cytokine levels with the pathological features and prognosis of the CRC was investigated. IL-10 levels in the sera of patients and controls were measured by Enzyme-linked immunosorbent assay. RESULTS: Mean serum IL-10 levels were significantly lower in CRCpatients than in controls (P = 0.04). CRCpatients with worse prognosis at the time of diagnosis tend to have higher levels of circulating IL-10 than those with better prognosis (P = 0.008). Receiver operating characteristics curve analysis demonstrated that IL-10 levels in the sera of CRCpatients can be used as a prognostic biomarker in CRCpatients (area under the curve = 0.71; P = 0.01). CONCLUSIONS: Our results demonstrated a dual association of serum IL-10 levels in the initiation and progression of CRC. While lower IL-10 levels were associated with higher risk of the disease, its higher levels were associated with a poorer prognosis.
Authors: Marta Kaleta-Richter; David Aebisher; Dagmara Jaworska; Zenon Czuba; Grzegorz Cieślar; Aleksandra Kawczyk-Krupka Journal: Integr Cancer Ther Date: 2020 Jan-Dec Impact factor: 3.279
Authors: Ioannis Karagiannidis; Eliane de Santana Van Vilet; Erika Said Abu Egal; Brandon Phinney; Damian Jacenik; Eric R Prossnitz; Ellen J Beswick Journal: Cancers (Basel) Date: 2020-10-06 Impact factor: 6.639
Authors: David A Simon Davis; Sahngeun Mun; Julianne M Smith; Dillon Hammill; Jessica Garrett; Katharine Gosling; Jason Price; Hany Elsaleh; Farhan M Syed; Ines I Atmosukarto; Benjamin J C Quah Journal: PLoS One Date: 2022-02-28 Impact factor: 3.240